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Summary 
Malaria is arguably one of the main medical concerns worldwide because of the numbers of people 
affected, the severity of the disease and the complexity of the life cycle of its causative agent, the 
protist Plasmodium spp. With the advent of nanoscience, renewed hopes have appeared of finally 
obtaining the long sought-after magic bullet against malaria in the form of a nanovector for the 
targeted delivery of antimalarial compounds exclusively to Plasmodium-infected cells, thus 
increasing drug efficacy and minimizing the induction of resistance to newly developed therapeutic 
agents. Poly(amidoamine) (PAA)-derived nanovectors combine into a single chemical structure 
drug encapsulating capacity, antimalarial activity, low unspecific toxicity, specific targeting to 
Plasmodium, optimal in vivo activity, and affordable synthesis cost. After having shown their 
efficacy in targeting drugs to intraerythrocytic parasites, now PAAs face the challenge of 
spearheading a new generation of nanocarriers aiming at the malaria parasite stages in the mosquito 
vector. 
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Malaria: a main health concern with an economic bias 
Progress in shrinking the geographical range of endemic malaria has been remarkable, and since the 
launching of the World Health Organization (WHO)-led Global Malaria Eradication Campaign in 
1955, 79 countries have eliminated malaria and the proportion of the world’s population living in 
endemic regions has decreased more than 50% [1]. Fifty years ago, malaria had been eliminated 
from many areas of the world through a combination of drug treatments and vector control 
interventions [2]. However, efforts were gradually abandoned from 1969 to 1976 due to the 
realization that the objective of eradication was unlikely to be easily achieved: the imperviousness 
of the vector to insecticides and the evolution of drug-resistant parasite strains severely impaired the 
WHO program [3]. In the 1990s control strategies were accelerated [4] through  the creation of 
several research and public health coalitions, such as the Multilateral Initiative on Malaria, the 
Global Fund to Fight AIDS, Tuberculosis and Malaria, the U.S. President’s Malaria Initiative and 
the Roll Back Malaria Partnership. 
Increased prevention and control measures have led to a reduction in malaria mortality rates 
by more than 42% globally since 2000. However, an estimated 3.3 billion people are at risk of being 
infected and developing symptoms, and 1.2 billion are at high risk (>1 in 1000 chance of getting 
malaria in a year) [5], particularly in Africa, where the annual economic burden of the disease has 
been calculated to be around 12 billion US$ in direct costs and to reduce GDP growth by 1.3% [6]. 
According to recent estimates, 198 million cases of malaria occurred worldwide in 2013 
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(uncertainty range 124-283 million) and the disease led to 584,000 deaths (uncertainty range 
367,000-755,000), but an independent study suggests that mortality could be twice as much if 
untreated and undiagnosed cases are included [7]. People living in the poorest countries are the 
most vulnerable, with approximately 90% of deaths in Africa, of which 78% were children under 5 
years of age [8,9]. International and domestic funding for malaria control and elimination totaled 
US$ 2.7 billion in 2013 [5]. Although this represented a threefold increase since 2005, it is still 
significantly below the estimated US$ 5.1 billion that is required to achieve global targets for 
control and elimination. Total malaria funding will only match resource needs if international and 
domestic funders prioritize further investments for malaria control [5]. The current trend of global 
warming and generalized transcontinental travel, added to the growing number of displaced 
populations in endemic areas due to political and economic reasons, threatens with expanding the 
disease range. Malaria eradication is now on the global research agenda [10], but current vaccines 
in clinical assays do not offer prospects of complete protection [11] and the available drugs are 
rapidly losing efficacy. Thus, there is an urgent need to invest in the development of new medicines 
and therapeutic strategies [12,13] working through radically new mechanisms. These new 
approaches should ideally: (i) address drug-resistance issues, (ii) have a rapid onset of action, (iii) 
be safe, and (iv) cure malaria in a single dose. 
 
Pathophysiology of malaria 
Five Plasmodium species cause disease in humans, namely P. vivax, P. ovale, P. malariae, P. 
knowlesi [14] and P. falciparum, with the latter being responsible for the most deadly and severe 
cases. When taking a blood meal, the female Anopheles mosquito inoculates Plasmodium 
sporozoites (Figure 1) that in the liver infect hepatocytes and proliferate into thousands of 
merozoites [15]. Merozoites invade red blood cells (RBCs), and replicate asexually through ring, 
trophozoite and schizont stages to produce daughter cells that invade new RBCs to perpetuate the 
blood-stage cycle. Some parasites eventually differentiate into sexual stages, female or male 
gametocytes that are ingested by a mosquito from peripheral blood. Following fertilization in the 
insect’s midgut, the zygote differentiates into an ookinete that moves through the midgut epithelium 
and forms an oocyst, which releases sporozoites. The malaria transmission cycle is restarted when 
sporozoites migrate to the salivary glands and are injected into a human with the mosquito’s next 
bite. Because the blood-stage infection is responsible for all symptoms and pathologies of malaria, 
Plasmodium-infected RBCs (pRBCs) are a main chemotherapeutic target [16]. Since antimalarial 
drug delivery currently relies on compounds with little or no specificity for pRBCs, the 
administration of most drugs requires high doses. However, such unspecificity often demands a low 
upper concentration threshold to minimize undesirable side-effects in non-target cells, thus 





Figure 1. Life cycle of the malaria parasite. Transmission of malaria occurs through a vector, the 
mosquito, which ingests gametocytes ‒the sexual form of the parasite‒ when feeding on an infected 
human. Male and female gametocytes mate in the mosquito gut, undergo meiosis, and then migrate 
through the midgut wall to form an oocyst, within which thousands of sporozoites develop. These 
are then injected into a human during the next blood meal(s), where they rapidly make their way to 
the liver, infect hepatocytes and begin asexually (mitotically) replicating. After a period of ca. 6–15 
days the liver schizonts rupture, releasing thousands of merozoites into the blood where they invade 
red blood cells, inside which the parasite progresses through a set of stages (ring, trophozoite and 
schizont) and produces an average of 16 new daughter merozoites per schizont. The schizonts then 
burst in near synchrony with other parasites, producing the characteristic fever cycle that embodies 
the clinical manifestations of the disease. With each replication, some of the merozoites develop 
into gametocytes, which can then infect susceptible mosquitoes, bringing the transmission cycle full 
circle. From [18], with permission. 
 
Nanotechnology against malaria 
Because malaria pathophysiology is so complex and the disease is so widespread, it is generally 
accepted that to achieve eradication a combination of weapons will be needed [19]. These include 
the improvement of existing approaches and the development of new ones [20], with drug therapy 
remaining the mainstay of treatment and prevention [21], and nanotechnology being able to provide 
innovative useful tools [22]. The objective of delivering drugs exclusively to a selected target site 
with minimal exposure for adjacent healthy cells or tissues is the holy grail of the fast-developing 
nanomedicine field [23]. Encapsulation of drugs in targeted nanovectors is a rapidly growing area 
with a clear applicability to infectious disease treatment [24], and pharmaceutical nanotechnology 
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has been identified as a potentially essential tool in the future fight against malaria [25,26]. 
Nanomedicine, which uses nanosized tools for treatment of disease [27], can fulfill the objective of 
achieving the intake of total amounts sufficiently low to be innocuous for the patient, but locally 
still lethal for the parasite. Mainly because of the lack of economic incentives, the application of 
nanotechnology to malaria has been traditionally neglected: a search in the Web of Science for the 
terms “nanomedicine” and “malaria” yields only ca. 30 peer-reviewed publications. The reasons for 
this gap in nanomedical research are surely varied, but among them are the lack of interest of a 
profit-seeking industry and the timid support of public administrations to small groups working off 
the main path of developed world diseases. Actually, the implementation of novel delivery 
approaches is less expensive than finding new antimalarial drugs and may optimize their rate of 
release [28]. Current immunoliposomal prototypes engineered for the delivery of antimalarial drugs 
specifically to pRBCs [29,30] rely on antibody targeting and contain special lipids, making their 
synthesis too expensive for practical widespread use in the routine treatment of most malaria cases, 
which are in regions with limited economic resources. An essential aspect for the successful 
development of antimalarial nanomedicines resides on the choice of encapsulating and targeting 
elements, of which it has to be considered their biocompatibility, cell specificity, binding affinity, 
ease of modification and conjugation to the drugs, production cost, scalability, amenability to oral 
administration formulation, and stability in mass production. Polymers offer virtually unlimited 
diversity in chemistry, dimensions and topology, rendering them a class of materials that is 
particularly suitable for applications in nanoscale drug delivery strategies [31]. 
 
Poly(amidoamine)s 
Poly(amidoamines)s (PAAs) are a family of biodegradable and biocompatible polymers whose 
synthesis was reported more than 40 years ago [32] and since then they have been used in different 
fields [33], among which biomedical applications are prominent [34]. The preparation process of PAAs 
is simple, environmentally friendly and easily scalable, thus being suitable to be commercialized in 
regions characterized by low per capita income. PAAs can be synthesized by Michael type 
polyaddition of primary or bis-secondary amines to bis(acrylamide)s (Figure 2). The structures 
obtained present tert-amino and amido groups regularly arranged along the main chain, being in the 
absence of additional acid or basic substituents low to medium strength polymeric bases that can be 
classified as polyelectrolytes. PAAs are per se highly functionalized, but are also amenable to further 
chemical modification for special applications. Groups capable of reacting with activated double bonds 
under the conditions of PAA synthesis (SH, NH2, NR and PH2) cannot be introduced directly but 
instead they can be obtained by functionalization of purposely pre-synthesized polymers. Amphoteric 
PAAs derive from aminoacids or from carboxylated bis-acrylamides and carry both carboxyl and 
amino groups attached to the same monomer, and therefore in solution they change their net average 
charge as a function of pH. By appropriately choosing the starting monomers, acidic and basic 
strengths of amino and carboxyl groups can be controlled in a way that the polymer switches from a 
prevailingly anionic to a prevailingly cationic state as a consequence of relatively modest pH changes 
[33]. 
 
Figure 2. Synthesis of linear PAAs. R1, R2, R3 and R4 can be any alkyl residue eventually 




The PAA polymerization reaction takes place in solvents carrying mobile protons, like water or 
alcohols, without the need for catalysts at room temperature [35,36]. High temperatures accelerate the 
polyaddition reaction rate but the resulting polymers have a lower molecular mass because of increased 
hydrolysis. PAA number- and weight-average molecular masses usually range between 5,000-40,000 
and 10,000-70,000 respectively, with a polydispersity index of 1.5-2 depending on the purification 
method used after synthesis. Narrow polydispersity fractions can be obtained by fractionation 
techniques, such as ultrafiltration, size exclusion chromatography or field-flow fractionation. Non-
amphoteric PAAs are soluble in water, but also in chloroform, lower alcohols, dimethyl sulfoxide and 
other polar solvents; on the other hand, amphoteric PAAs dissolve only in water. PAAs exhibit 
relatively large hydrodynamic volumes in solution if compared with vinyl polymers of similar mass, 
indicating a tendency to assume extended chain conformations in solution [34]. By introducing 
multifunctional amines in the polymerization mixture crosslinked structures can be obtained, which 
usually absorb large amounts of water and form hydrogels in aqueous media [37]. These hydrogels 
have been proven to possess good mechanic properties, biocompatibility, biodegradability and ability 
to induce cell adhesion and proliferation [38]. In aqueous media PAAs degrade within days or weeks to 
oligomeric products [39,40], in a process strongly influenced by the structure of amide and amine 
moieties that increases at basic pH and higher temperatures (40-60 °C). The degradation mechanism 
seems to be purely hydrolytic and not affected by the presence of lysosomal enzymes at pH 5.5 [41]. 
The toxicity of PAAs and their low molecular mass degradation products is two or more orders of 
magnitude lower than that of other polycations such as poly-L-lysine, polyethyleneimine or PAMAM 
dendrimers [34]. Amphoteric PAAs that at pH 7.4 are mostly negatively charged are found to be non 
toxic, whereas strongly basic polymers positively charged at the same pH display significant 
cytotoxicity [42]. All PAAs cause more hemolysis at pH 5.5 than at pH 7.4 because protonation of the 
polymer backbone in acidic conditions increases its capacity to interact with and desestabilize the 
anionic RBC membrane [43]. 
 
PAA applications in drug delivery 
Whereas some PAAs are captured by the liver or the kidney rapidly after i.v. injection [42], others 
circulate in the bloodstream for an extended period [44], showing a tendency to localize in tumours 
due to the enhanced permeability effect. This long blood residence time is an important feature to 
consider when selecting candidates for the design of drug delivery systems, since an increased 
circulation will facilitate interactions of polymers with the target cell, which usually internalizes 
them via the endocytic pathway [45]. PAAs were first tested for their ability to form polyelectrolyte 
stable complexes with heparin, in order to neutralise its anticoagulant activity [34,46], results later 
extended to PAA-crosslinked resins, which have also been assayed for metal ion complexation [47]. 
Depending on their polymer content and formulation, these resins were able to incorporate from 30 
to 100% w/w of heparin, without affecting other blood parameters [48]. Early in the 1970s several 
PAAs were shown to display inherent antitumour activity, reducing the number and average weight 
of Lewis lung tumour metastases after i.v. administration in mice, with different grades of toxicity 
and activity, although none of them were active against the primary tumour [49]. More recently, 
PAAs have been adopted as carriers for anticancer drugs such as mytomycin C [50], platinates [51] 
and doxorubicin. Conjugation of doxorubicin to polymers improves drug solubility, increases its 
blood half-life, decreases its toxicity, and mediates more efficient tumour targeting [52]. As the 
drug is inactive in its conjugated form and can be selectively released at the tumour site, 
doxorubicin can act primarily against cancer cells with minimal damage to healthy tissue. 
Doxorubicin has also been coupled to polymers via an acid-sensitive linker, facilitating the release 
of the drug in a biologically active form in the endosomal compartment [53]. 
As a promising tool to treat a variery of diseases, PAAs have been used as carriers for RNA and 
DNA as transfection promoters [54-57]. In particular, PAA polymers synthesized from bisacrylamides 
and incorporating a carboxylic acid group have been reported to achieve transfection efficiencies 
comparable to polyethyleneimine, the gold standard for polymer-assisted gene transfection, but with a 
significantly lower cytotoxicity [56]. Different modifications of PAAs have been published, for 
6 
 
instance incorporating repetitive disulfide links in the main chain [58], linear or branched architectures 
[59], intercalating quaternary nicotinamides [55] and boronic acid moieties [54] as side groups, in 
order to combine stability of the polyplexes, high transfection efficiencies and low unspecific 
cytotoxicity [60]. In vitro assays demonstrated the ability of the polymers to form stable polyplexes, to 
interact with cell membranes in a non-disruptive way, to protect DNA from enzymatic degradation in 
the biological environment and to promote stable gene transfection in living cells [61]. PAAs have 
been found to be particularly suitable for the intracellular delivery of peptides and proteins [62,63],
 
which can be inserted for targeting purposes either as pendants or as integral portions of the polymer 
chain. Different functionalized PAAs have been optimized to obtain a fast and efficient protein release 
with lysozyme as a model cationic protein [63] or with β-galactosidase, which was successfully taken 
up into cells, whereas the enzyme alone could not be internalized [64]. These polymer-protein 
complexes are stable in extracellular media but disintegrate into low molecular mass fragments once 
inside the cells. The (partial) release of proteins from the complexes is induced by charge reversal at 
endosomal pH, leading to decreased protein–polymer interaction, and by polymer degradation due to 
intracellular reduction of polymer disulfide linkages. Endosomal escape of the nanovessel and its cargo 
will depend on the different functionalities present in the polymer [65], e.g. positively charged groups 
are expected to have increased interactions with the membrane of the organelle and promote 
endosomal disruption [58]. Other PAA derivatives, such as branched polymers with arginine, maintain 
the cell internalization capacity of the amino acid, but having increased biocompatibility than arginine-
rich cell penetrating peptides [66]. PAAs have been used as carriers for the antiviral compound 
Acyclovir [67], where in vitro experiments showed that polymer conjugation of the drug increased its 
activity. More recent results [68,69], indicate that agmatine-containing PAAs possess antiviral activity 
which is not a mere consequence of cytotoxicity. 
 
PAAs for the targeted delivery of antimalarial drugs 
The PAA structures AGMA1, ISA1 and ISA23 (Figure 3) have been explored for the encapsulation 
and targeted delivery of the antimalarial drugs chloroquine and primaquine [70]. 
 
 
Figure 3. Chemical structures of the PAAs AGMA1, ISA1, and ISA23. 
 
AGMA1 is obtained by polyaddition of 4-aminobutylguanidine (agmatine) with 2,2-
bis(acrylamido)acetic acid and contains tert-amine, carboxyl and guanidine groups. It is amphoteric 
with isoelectric point 10.0 and therefore at pH 7.4 is prevailingly cationic with, on average, 0.55 
excess positive charges per unit. ISA23 is obtained by polyaddition of 2-methylpiperazine with 2,2-
bis(acrylamido)acetic acid. Notwithstanding carrying two tert-amine groups and one carboxyl 
group per unit, it has isoelectric point 5.5, being prevailingly anionic at pH 7.4 with, on average, 
0.38 excess negative charges per unit. ISA1 is obtained by polyaddition of bis(acryloyl)piperazine 
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with 2-methylpiperazine and bis(hydroxyethylethylenediamine). It is a rather weak polymeric base 
with, on average, 0.55 positive charges per unit at pH 7.4. All these polymers had been reported as 
vectors for the intracellular delivery of nucleic acids [56,61,71], whereas ISA1 and ISA23 had been 
also studied for protein delivery [45,62,71] and as anticancer drug carriers [51,53]. ISA23 in 
particular has been proven to be endowed with stealth-like properties without selectively 
concentrating in the liver [44], while a significant portion of AGMA1 did show hepatic localization 
after intravenous injection in mice [42]. In intracellular compartments where the pH decreases to 
6.5 (endosomes) and then to 5.0 (lysosomes), PAAs become prevailingly cationic and display 
endosomolytic properties [72]. Fluorescence microscopy revealed colocalization of ISA1 and 
ISA23 with Lysotracker, a marker for lysosome and late endocytic structures, and ISA1 also 
colocalized with the Early Endosomal Antigen 1 that accumulates in early endocytic structures [45]. 
Atomic force microscopy images (Figure 4) revealed a globular conformation for AGMA1, ISA23 
and ISA1 adsorbed on mica substrates, showing a homogenous polymer size distribution with a 




Figure 4. Atomic force microscope images in liquid of different fractions of AGMA1 (A-D) and 
ISA1 (E), of non-fractionated ISA23 (F), and of AGMA1 encapsulating the antimalarial drug 




pRBCs are known to be permeable to high molecular mass solutes up to diameters of 70 nm 
[73,74], including peptides and proteins, with which PAAs share some features, such as the 
polyelectrolyte behavior and the presence of amide groups in the main chain. This led us to explore 
the potential of ISA1, ISA23 and AGMA1 as antimalarial drug carriers. Fluorescence-assisted cell 
sorting, confocal immunofluorescence and transmission electron microscopy results indicated that 
the tested polymers have specific targeting to pRBCs, and subcellular targeting to the parasite itself 
(Figure 5). In 4-day suppressive tests, mice infected with a lethal strain of the murine malaria 
species Plasmodium yoelii were freed of parasites and cured after intraperitoneal administration of 




, whereas the same 
amount of free drug was unable to cure the animals [70]. PAAs targeted different Plasmodium 
species and AGMA1 in particular possessed significant intrinsic antimalarial activity per se, 
showing binding to merozoites and probably inhibiting their invasion of new red blood cells. The 
ensuing prolonged exposure of the pathogens to the immune system might be applied to the design 
of new malaria vaccination approaches where PAAs could play a dual role as carriers of 
antimalarial drugs and as vaccination adjuvants. This unexpected synergistic effect combining 
therapeutics and prophylaxis represents a radically new approach to the treatment of malaria for 
which we propose the term theralaxis. 
 
 
Figure 5. Confocal fluorescence microscopy targeting study of AGMA1 and ISA23 to P. 
falciparum and P. yoelii. FITC-labeled ISA23 (A) or AGMA1 (B) were added to either P. yoelii-
infected mouse blood, or to living P. falciparum cultures of the 3D7 strain, respectively. After 90 
min of incubation the samples were processed for confocal fluorescence microscopy analysis. PAA-
FITC localization is shown in green, DAPI (blue) staining of Plasmodium nuclei was used to reveal 
the parasites, and the RBC plasma membrane is shown in red. From [70], with permission. 
 
Antimalarial drug delivery to mosquitoes 
Current chemotherapeutic approaches against malaria are targeted at the asexual, blood-stage 
parasites responsible for all symptoms and pathologies of the disease [16]. However, as in the 
bloodstream of a malaria patient there can be several hundred billion pRBCs, multiple-dose 
administrations of drugs are usually required to clear infections. This continuous exposure of 
Plasmodium to antimalarials increases the likelihood of resistance evolution, which will rapidly 
decrease drug efficacy. The threat of resistance-driven treatment failure is prompting research 
oriented to targeting the weakest forms of the pathogen represented by smaller populations, which 
are less likely to contain resistant individuals that would benefit from the removal of susceptible 
parasites [75]. The two main bottlenecks in the malaria cycle are found where the parasite is in one 
of the transmission stages that move between hosts [76]. A few thousand sporozoites can be packed 
inside the mosquito salivary glands, but only approximately 100 will be transferred to the human 
when Anopheles bites; this is several orders of magnitude fewer parasites than are found in an active 
blood stage infection. However, the short time that free sporozoites remain in the circulation is a 
serious obstacle to targeting them. A second bottleneck occurs during sexual development, when ca. 
0.2-1% of the intraerythrocytic parasites may develop into gametocytes per round of schizogony. 




 parasites to be cleared from the blood circulation, 
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targeting gametocytes can ease exposure of the pathogen to drugs and reduce the likelihood of 
resistance emerging [76]. 
However, a largely unexplored avenue in antimalarial drug development is targeting the 
parasite stages in the insect vector itself [77], an approach being barely investigated in the 
laboratory, and not implemented yet as part of a clinically feasible alternative therapy. Although the 
innate immune system of mosquitoes is capable of completely clearing a malaria infection [78], it is 
far from the sophisticated arsenal providing long-term protection in mammalian adaptive immunity. 
This might result in mosquito stages of Plasmodium having reduced defenses because they need to 
survive just a few days facing an immune surveillance not as demanding as in the human host. In 
addition, the richness of biological processes required for development in the mosquito likely 
withdraws from the parasite metabolic resources otherwise allocated to drug resistance. Drugs 
targeting early Anopheles stages must kill only ca. 5  103 parasites to free a mosquito from 
Plasmodium infection [79], and the absolute low corresponds to oocysts, of which there are only 2-
5 in a single insect [76], being around for over a week. The recent appreciation that decreasing 
malaria prevalence requires strategies to reduce transmission through the mosquito [80] has 
prompted a renewed search for alternative therapeutic approaches. Unlike the asexual parasites, 
Plasmodium transmission forms are difficult and expensive to propagate and handle in the 
laboratory, but the first practical steps that shall eventually make possible these new objectives are 
being taken in the form of incipient protocols for the purification of P. falciparum ookinetes [81], 
although their culture has not been standardized [82,83]. P. vivax ookinetes can be grown in culture 
[84], but implementation of this assay would require both the stable transfection of the parasite, a 
process not yet achieved [85], and the routine availability of viable gametocytes en masse, currently 
not possible from culture. Gametocyte-to-ookinete development can be reproduced successfully in 
vitro for the rodent malaria parasite P. berghei [86]. However, these alternative cell targets incur the 
significant problem of their in vivo location in the mosquito. 
Two approaches seem to offer some hope of being able to deliver transmission-blocking drugs 
to Anopheles, but it is difficult to say which one poses more daunting obstacles. Because 
gametogenesis, fertilization, and zygote differentiation into an ookinete occur in the mosquito 
within an environment essentially consisting of human blood, any compound affecting these 
processes can be delivered via the very blood meal of the insect. Thus, we can consider 
administering to humans antimalarials with a sufficiently long blood half-life to have good chances 
of being taken up by a mosquito during its bite. According to approximate estimates this might 
mean between 3 or 4 weeks in the blood of people living in endemic areas. In addition to patient 
compliance, we face the challenge of finding a drug escaping spleen and liver clearance and kidney 
filtration for a formidably long time span, and which in the end has to be present at therapeutic 
concentration in the infected insect. To the best of our knowledge, the only example of drug 
administration in this way to mosquitoes is the case of ivermectin [87], an insecticide which, at 
concentrations found in human blood after treatment, is toxic to all Anopheles species examined. 
However, the insect has to blood-feed on a treated subject (i.e. patient compliance is a parameter to 
consider), and resistances to ivermectin have been already documented [88]. 
 
Direct antimalarial drug administration to mosquitoes 
The alternative to administering antimalarials to mosquitoes via human blood through the insect’s 
blood meal is even more mind-boggling: delivering the drug directly to Anopheles. For this 
approach to work it is a must that the mosquito should have the need to ingest something between a 
first blood meal where gametocytes have been taken and the second infective bite once Plasmodium 
sporozoites have developed. There seems to be a lack of consensus as to whether during that time 
lapse Anopheles either rests in a secluded spot, or it does eventually drink some substance. But even 
if the mosquito is satiated for weeks following a blood meal, the very biology of the malaria 
parasite might assist us here. To keep blood fluid and prevent quick coagulation, Anopheles 
synthesizes an anti-hemostatic armamentarium containing, among others, the enzyme apyrase. 
Plasmodium inhibits apyrase [89] and in this way entices the mosquito to bite more because blood 
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coagulates faster and Anopheles has to probe longer to get its full dinner, thereby increasing 
potentially infective host contacts. It can be expected then that infected insects will have a larger 
probability of probing a non-human source. 
While female mosquitoes depend on protein-rich blood meals for egg maturation, both male 
and female mosquitoes are also attracted to and feed from plants. Plant nectar is an important, 
carbohydrate-rich nutrient source that provides essential energy for flight and, for some mosquito 
species, overwintering [90,91]. This phytoattraction has been successfully harnessed by malaria 
control efforts through attractive nectar baiting strategies, in which mosquitoes are lured to sugar-
water blends spiked with plant volatiles and insecticides [92,93]. Suspected preferred host plants for 
Anopheles gambiae include Asteracaeae spp. and Ricinus communis [94]. Analysis of purified 
odorants from these plants has revealed enrichment of volatile compounds known as terpenes, 
including 10-carbon monoterpenes such as pinene and limonene, which at low concentrations have 
been shown to mediate attraction of Anopheles spp. [94,95]. Several approaches are currently 
available for oral delivery to mosquitoes by droplet or liquid feeding, through dry diets [96], or via 
nylon strips continuously dispensing synthetic mosquito attractants for several weeks [97,98]. Some 
of these methods have been already used to deliver to dipterans lipid-based [99] and chitosan 
nanoparticles [100]. Because Anopheles males can be easily fed from drug-containing sugar-baited 
traps, unlike females whose blood meal feeding habits complicate the design of a surrogate blood 
diet, it would be advisable to investigate the possible horizontal transfer of antimalarial drugs 
through sperm. Another interesting, though challenging, alternative to administering PAA-
encapsulated drugs to adult mosquitoes with the objective of eliminating Plasmodium from infected 
insects, is delivery to mosquito eggs. In such strategy, if PAA nanocarriers can be made to persist 
throughout metamorphosis, emerging mosquitoes might be endowed with prophylactic antimalarial 
capacity. A number of chemicals have been proposed as oviposition attractants for A. gambiae 
[101,102], with the sesquiterpene alcohol cedrol as one of the most promising candidates [103]. 
Highly concentrated drugs against Plasmodium gametes, ookinetes, oocysts or sporozoites 
could be directly dispensed to mosquitoes from fixed-volume containers where the drug does not 
become diluted with time as when it circulates in human blood. Such a strategy, because it is not 
designed for administration to humans, will bypass clinical trials that often delay for years the 
deployment of a new medicine, and will significantly reduce treatment development costs. 
Mosquito-dwelling transmission forms will likely be efficiently reached by specifically targeted 
nanovectors encapsulating the corresponding drugs, which in this way are protected from 
degradation before being ingested by the insect. A final bonus of delivering the nanocarriers 
directly to mosquitoes is that the usable nanoparticle size range becomes greatly expanded between 
a few nm and up to several microns for the direct delivery to females. Administration to insects will 
allow also for a not so strict vigilance on other nanocarrier characteristics such as zeta potential, 
toxicity of the chemical units constituting the nanovector, the nature, type and number of targeting 
units, or the nature, number, and amount of drug(s) loaded. 
 
Targeting mosquito stages of Plasmodium 
The three elements that constitute a targeted therapeutic nanovector (nanocapsule, targeting 
molecule and the drug itself) can be exchanged, as if they were LEGO parts, to obtain new 
structures better suited to each particular situation. Through modification of its constituting 
elements, nanovector design is susceptible of improvement and of adaptation to new targets such as 
different Plasmodium species or infected cells other than the erythrocyte. Of particular interest here, 
as discussed above, is the targeting of the transmission stages that allow transfer of the parasite 
between human and mosquito and vice-versa, which represent the weakest spots in the life cycle of 
the pathogen [77]. Heparin and heparan sulfate are targets for the circumsporozoite protein in the 
sporozoite attachment to hepatocytes during the primary stage of malaria infection in the liver 
[104]. Chondroitin sulfate proteoglycans in the mosquito midgut and synthetic chondroitin sulfate 
mimetics have been described to bind Plasmodium ookinetes as an essential step of host epithelial 
cell invasion [105,106], whereas ookinete-secreted proteins have been found to possess significant 
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binding to heparin [107]. A synthetic polysulfonated polymer that mimics the structure of 
glycosaminoglycans present in the mosquito midgut surface has been used as a proof of concept for 
a transmission-blocking strategy [106]. The authors showed that the inhibition of Plasmodium 
development in the mosquito could be achieved by interfering in the interaction between the 
parasite and the mosquito midgut epithelium, which is a key step in the life cycle of the pathogen. 
This body of accumulated evidence suggests that glycosaminoglycans might be adequate to target 
antimalarial-loaded PAA-based nanovectors to Plasmodium mosquito stages, either through a direct 
entry into gametocytes, ookinetes, and sporozoites, or indirectly through delivery to pRBCs for 
those that will later differentiate into gametocytes. 
Phenomenal experimental obstacles loom above this approach, which could only be pushed 
forward with a truly multidisciplinary research team involving chemists, physicians, entomologists, 
environmentalists, biochemists, evolutionary biologists, nanotechnologists, and many other 
professionals. Although eliminating a handful of oocysts in a bug seems easy enough, the sheer 
numbers of mosquitoes that have to be reached represents a challenge that will require a deep 
understanding of insect behavior and, likely, the development of new antimalarial drugs working 
through radically new mechanisms. But, if we take the pain of targeting the mosquito, wouldn’t it 
be better just delivering insecticide? However, by wiping off an insect species we might be 
unbalancing the ecosystem in unpredictable ways, not to mention that besides Anopheles, the 
concocted broth can be a delicatessen for many other insects, some of them with known essential 
functions e.g. as pollinators, whose eradication might bring crop collapse and famine. 
 
Future perspective 
Future antimalarial strategies relying on drugs working through radically new mechanisms might 
demand direct delivery to Plasmodium stages in the mosquito of PAA-based targeted nanovectors 
loaded with these new medicines. The specifications to which the nanocarriers will likely have to fit 
are (i) a simple and scalable synthesis with affordable cost, (ii) the capacity to encapsulate a wide 
range of antimalarial drug structures, (iii) a long half-life of months without losing integrity before 
being ingested by the mosquito while preserving drug activity, (iv) an adequate degradation rate 
once inside female Anopheles to allow the drug entering Plasmodium, (v) a slower degradation rate 
once inside male Anopheles to allow the nanocarriers being horizontally transferred to females upon 
mating, (vi) a high solubility in mosquito artificial diets to allow for the maximum affordable 
concentrations, and (vii) a targeting as specific as possible to Plasmodium stages inside Anopheles 
(gametocytes, ookinetes, oocysts and sporozoites). As we have discussed above, PAA-based 
nanocarriers can fulfill these requirements and thus significantly contribute as a new weapon in a 
future scenario of malaria eradication. 
 
Executive summary 
Malaria: a main health concern with an economic bias 
• There is an urgent need to invest in the development of new antimalarial medicines and 
therapeutic strategies working through radically new mechanisms. 
Pathophysiology of malaria 
• The unspecificity of toxic drugs demands low concentrations to minimize undesirable side-effects, 
thus incurring the risk of sublethal doses favoring the evolution of resistant Plasmodium strains. 
Nanotechnology against malaria 
• Drug therapy remains the mainstay of treatment and prevention against malaria, with 
nanotechnology being able to provide innovative useful tools. 
• Pharmaceutical nanotechnology has been identified as a potentially essential tool in the future 
fight against malaria. 
• Nanomedicine can fulfill the objective of achieving the intake of total amounts sufficiently low to 
be innocuous for the patient, but locally still lethal for the parasite. 
• Mainly because of the lack of economic incentives, the application of nanotechnology to malaria 
has been traditionally neglected. 
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• The development of novel delivery approaches is less expensive than finding new antimalarial 
drugs. 
Poly(amidoamine)s 
• The preparation process of PAAs is simple, environmentally friendly and easily scalable, thus 
being suitable to be commercialized in regions characterized by low per capita income. 
PAA applications in drug delivery 
• PAAs have been found to be particularly suitable for the intracellular delivery of peptides and 
proteins. 
PAAs for the targeted delivery of antimalarial drugs 
• PAAs have been shown to be targeted to Plasmodium. 
Antimalarial drug delivery to mosquitoes 
• A largely unexplored avenue in antimalarial drug development is targeting the parasite stages in 
the insect vector itself. 
Direct antimalarial drug administration to mosquitoes 
• Drug delivery to mosquitoes, because it is not designed for administration to humans, will bypass 
clinical trials that often delay for years the deployment of a new medicine. 
Targeting mosquito stages of Plasmodium 
• Glycosaminoglycans might be adequate to target antimalarial-loaded PAA-based nanovectors to 
Plasmodium mosquito stages. 
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